'Cooling' mattress and pillows leaves shoppers 'sleeping like a dream'
While the hot weather can be lovely while sunbathing, it's less comfortable when it's time to go to bed. Tossing and turning in sweaty bedsheets is a cruel reality of summer nights, but the right bedding can make the world of difference for a comfortable night's sleep.
Until Monday, shoppers can save up to 20% on Emma's range of cooling mattresses, pillows and more, making it easier to get a good night's sleep in the heat. There are loads of products in the sale from duvets to pillows, mattresses to sheets, and plenty are designed to help buyers keep cool in the summer.
For example, the Emma Hybrid Thermosync Mattress is now £655.20 down from £819 for a double size. It's designed with ThermoSync technology which helps to regulate body temperature, and it also absorbs motion on the mattress so fidgeting partners won't interrupt precious sleep.
The mattress is also available in UK single for £415.20 down from £519, small double for £580.80 down from £726, king size for £734.40 down from £918, or super king for £840 down from £1,050.
Shoppers can also save on the Emma Premium Foam Pillows, available either individually for £65.60 down from £82 or as a bundle of two for £123 down from £164. These pillows are temperature regulating with adjustable layers so users can change the height, with support for all sleeping positions.
If Emma's range isn't quite right for shoppers, they could take a look at the TEMPUR ONE SmartCool™ Mattress which is currently £999 at Dreams. This one's available in firm or medium, is made from memory foam, and has a SmartCool™ cover that reduces heat throughout the night.
Alternatively, there's the Luff Mayfair Cooling Gel Bamboo Pillow for £69.99 at Laud, which has a cooling pad, is naturally antibacterial, and is nice and firm.
However, Emma shoppers have shared how pleased they are with their purchases. One said: "Excellent mattress well worth every penny. Never have I slept as well."
Another said: "This mattress is very comfortable with the perfect level of support."
A third said of an Emma pillow: "Comfortable, not too big or too small, decent size sideways, very airy and comfortable, love it."
However, another mattress buyer said: "OK but not as firm as I thought it would be for the money."
A separate reviewer added: "So so happy with my new mattress and pillows. Sleeping like a dream So happy."
However, for big savings on a range that promotes a cool sleeping experience, the Emma sale is worth a look.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
North Wales Live
a day ago
- North Wales Live
Llandudno brewery with taproom plans further expansion after securing loan
One of North Wales' leading craft breweries has set its sights on further expansion and business growth after securing a £150k loan. Llandudno 's Wild Horse Brewing Co, which was established in 2015, secured a finance package from BCRS Business Loans, following an introduction by Bathgate Business Finance. The deal has assisted the company's future growth plans, whilst also supporting renovation work and renewable energy solutions. Wild Horse Brewing Co – on Cae Bach, Builder Street – has focused on a period of investment, expanding to purchase a permanent tap room whilst also installing solar panels. And with the tap room now attracting a growing customer base, whilst providing a venue for trade customers to sample the range of beers in the space in which they're brewed, the brewery sought to consolidate finance to move the business forward. Emma Faragher, who set up Wild Horse Brewing Co with husband Dave, said: 'Last year we sold 444,000 pints of our beer, and the majority of sales come directly from pubs, but there were opportunities we wanted to take advantage of to further expand the business. 'We had run a pop-up taproom on and off for a couple of years, but with the brewing space expanding to cope with sales demand, we were short of space to continue in the same fashion. Join the North Wales Live Whatsapp community now 'The tenant next door had been operating for over 40 years, so when the space came up for sale, we knew it was the right direction for our business and we needed to act fast.' Wild Horse Brewing Co were put in contact with Bathgate Business Finance, which then introduced Emma and Dave to BCRS Business Loans' business development manager, James Pittendreigh. Working together, the brewery was supported with a £150,000 finance package from BCRS Business Loans, via the British Business Bank's £130m Investment Fund for Wales and Community Investment Enterprise Fund (CIEF). Emma added: 'At previous junctions of the business, we had used our capital to allow us to purchase the site next door, in a timely fashion we looked at other opportunities. After securing the taproom, we knew that there were opportunities to consolidate the finance we had in place, and BCRS was fantastic and took the time to get to know the business and the journey we were on. 'Through the £30,000 funding from the Investment Fund for Wales, we've been able to carry out work to the car park area which has created more outdoor space for customers. 'This funding has been fantastic; without it we wouldn't have the same growth opportunities. 'The tap room is currently open Thursday to Sunday with ten rotating beers, and we're looking forward to attracting more customers through the doors, both trade and individual.' BCRS Business Loans' James Pittendreigh said: 'Emma, Dave, and the team at Wild Horse Brewing Co have come a long way in a relatively short period, and we're delighted to support them as they continue on their growth path. 'In supporting companies across Wales, we seek to work in partnership with our wider network, and this deal saw Williams Denton refer their customer to Bathgate, who in turn pointed Emma and Dave in the direction of BCRS.'
Daily Mirror
a day ago
- Daily Mirror
Dyson's bestselling Airwrap named the ‘best product ever' is £100 off for a limited time
Dyson has slashed £100 off its bestselling Airwrap for a limited time only, and shoppers have hailed it as a 'gamechanger' that makes styling hair so easy If you've been debating the idea of treating yourself to a Dyson Airwrap but have been put off by the almost £500 price tag, you're in luck. Dyson has slashed a rare £100 off for a limited time only. Normally priced at £479.99, the New Dyson Airwrap i.d.™ multi-styler and dryer with Diffuser in Vinca Blue/Topaz is now £379.99. Curly-haired girls will be pleased to see that the styler with the diffuser attachment is on offer. Styling your hair at home should feel like a relaxing, self-care moment, not an hour of stress and effort, and that's where the Airwrap comes in. Designed to create salon-worthy looks at home, this tool helps even those who are terrible at hair find the new Airwrap i.d. features a built-in Bluetooth and the My Dyson App, which essentially becomes your new hair stylist. You take a short quiz on the app explaining your hair type, and the Airwrap knows exactly what to do. It will adjust the timing, styling and even the cool shot for you. So you can switch off and end up with gorgeous, damage-free locks. The Airwrap has some glowing testimonials to back it up with shoppers calling it a 'game changer' and the best ever. One shopper wrote: "Wow, what an amazing product - I literally could not live without this air wrap. It's so easy to set up on the app and use and much lighter to hold that expected. I have little patience in styling my hair but this makes it so easy and within 5 mins I have a lovely bouncy blow dry or beach waves, my curls stay in for a couple of days. The flyaway attachment is unreal and gives me poker straight hair. " A second added: "The best product ever! My hair reborned since I started using it! Every woman should have it !". And a third praised: "Surprise birthday present - and it is such a game changer Hair drys in minutes and looks like it has been done professionally at a salon. I love it" It's worth noting, however, the Airwrap is not going to work wonders on every single hair type. One shopper criticised its inability to hold curls on dead straight hair. They wrote: "I do like it but the price for straight hair doesn't really stay on, but I love the look of curls but it won't last till 2h if it's really hot humid weather, specially if your hair dead straight." If you've not been tempted by the Airwrap, two of my current favourite hair tools include Drybar's Double Shot Blowdryer Brush. This is one of the only heated brushes that has given me sleek, bouncy hair that actually lasts, and is a damp-to-dry styler. Additionally, Remington's AIRvive™ 2-in-1 Air Styler is essentially a styling shortcut for smoother, sleeker hair without extreme heat damage.
Times
2 days ago
- Times
GSK profits lifted by strong cancer drug sales
Strong sales of specialty medicines during the first half of the year has led GSK to expect group revenue and profit growth towards the top end of its forecast range. The FTSE 100 company posted total second quarter sales of almost £8 billion, up 6 per cent at constant currencies and ahead of City forecasts of £7.8 billion. Specialty medicines rose 15 per cent to £3.3 billion, including cancer treatments up 42 per cent and HIV drug sales 12 per cent. Core operating profit rose 12 per cent to £2.6 billion in the quarter. • Business live: FTSE 100 drops on poor corporate results The performance led GSK to forecast revenue growth this year towards the top end of its previously-guided range of between 3 and 5 per cent. Similarly it expects core operating profit growth to be towards the top of its 6 to 8 per cent range. GSK said that its guidance reflected tariffs already enacted and the US-EU trade deal struck this week, adding that it was 'positioned to respond to the potential financial impact of tariffs, with mitigation options identified. Given the uncertain external environment, we will continue to monitor developments'. On Monday, President Trump reiterated threats to introduce tariffs on pharmaceutical imports soon as he seeks to pressure multinationals to increase manufacturing in the United States. Dame Emma Walmsley, GSK's group chief executive, said that the 'strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business'. She added: 'We also continue to make very good progress in R&D, with three major FDA approvals achieved so far this year, 16 assets now in late-stage development, and four more promising medicines to treat cancer, liver disease and HIV expected to enter phase III and pivotal development by the end of the year.' A dividend of 16p per share was declared and GSK has spent £822 million on its £2 billion share buyback, which was announced at its full-year results earlier this year. Shares in GSK slid 8p, or 0.5 per cent, to £13.89 in early trading in London. Walmsley, 56, who has led GSK since 2017, said that the company remained confident in its its long-term outlook. GSK has set a target of generating group sales of more than £40 billion by 2031. However, there remains scepticism among some investors that it will hit that figure, with consensus forecasts instead of just £34 billion. It suffered a setback this month when the Food and Drug Administration, the regulator in America, the world's biggest drugs market, delayed a decision on approving Blenrep, a potential blockbuster blood cancer drug. The European Union, however, approved Blenrep for the treatment of adults with relapsed or refractory multiple myeloma. The UK has also given the green light. GSK, based in London's 'Knowledge Quarter', is one of Britain's two big pharma companies alongside AstraZeneca. It employs more than 65,000 people and operates in 75 markets. The group separated Haleon, its consumer healthcare business, as a standalone FTSE 100 company three years ago to focus on developing its core biopharma pipeline and to give it more firepower for bolt-on deals. On Monday it struck a $500 million deal with Hengrui Pharma, a Chinese pharmaceutical company, to develop up to a dozen new medicines as it deepens its partnerships in the country. GSK said on Wednesday that its agreement in May to pay up to $2 billion for a promising liver disease drug, the lead asset of Boston Pharmaceuticals, a US biopharma company, had been completed.
